Scholar Rock Holding (SRRK) Accumulated Expenses (2017 - 2026)
Scholar Rock Holding's (SRRK) quarterly Accumulated Expenses came in at $44.3 million in Q1 2026, up 428.85% year-on-year from $8.4 million in Q1 2025, and up 12.09% quarter-over-quarter from $39.6 million in Q4 2025.
Scholar Rock Holding (SRRK) Accumulated Expenses (2017 - 2026) Analysis & Trends
Scholar Rock Holding's Accumulated Expenses history runs 10 years deep, the most recent figure standing at $44.3 million for Q1 2026.
- On a quarterly basis, Accumulated Expenses rose 428.85% year-over-year to $44.3 million in Q1 2026; TTM through Mar 2026 was $44.3 million, a 428.85% increase from a year earlier, with the FY2025 full-year figure at $39.6 million, up 167.77% from the prior year.
- Accumulated Expenses rose to $44.3 million in Q1 2026 per SRRK's latest filing, from $39.6 million in the prior quarter.
- Across five years, Accumulated Expenses topped out at $49.9 million in Q3 2025 and bottomed at $200000.0 in Q3 2022.
- The 5-year median for Accumulated Expenses is $14.7 million (2025), against an average of $17.1 million.
- Across the five-year window, Accumulated Expenses plunged 98.88% in 2022 and surged 8598.5% in 2023, its largest moves.
- Year by year, Accumulated Expenses stood at $6.8 million in 2022, then jumped by 55.75% to $10.6 million in 2023, then jumped by 39.51% to $14.8 million in 2024, then jumped by 167.77% to $39.6 million in 2025, then grew by 12.09% to $44.3 million in 2026.
- Per Business Quant, the three latest SRRK Accumulated Expenses figures stand at $44.3 million (Q1 2026), $39.6 million (Q4 2025), and $49.9 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Scholar Rock Holding | 6.30 Bn | 6.30 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 44.35 Mn |
| Dec 31, 2025 | 39.57 Mn |
| Sep 30, 2025 | 49.88 Mn |
| Jun 30, 2025 | 14.69 Mn |
| Mar 31, 2025 | 8.39 Mn |
| Dec 31, 2024 | 14.78 Mn |
| Sep 30, 2024 | 29.26 Mn |
| Jun 30, 2024 | 21.89 Mn |
| Mar 31, 2024 | 6.11 Mn |
| Dec 31, 2023 | 10.59 Mn |
| Sep 30, 2023 | 17.40 Mn |
| Jun 30, 2023 | 5.63 Mn |
| Mar 31, 2023 | 14.73 Mn |
| Dec 31, 2022 | 6.80 Mn |
| Sep 30, 2022 | 200,000.00 |
| Jun 30, 2022 | 1.40 Mn |
| Mar 31, 2022 | 4.47 Mn |
| Dec 31, 2021 | 7.15 Mn |
| Sep 30, 2021 | 17.90 Mn |
| Jun 30, 2021 | 15.45 Mn |